Biogen sale may hit snag: high price
Investors' giddiness subsides on fears a buyer won't surface
Biogen Idec Inc., the state's largest biotechnology company, is attempting to sell itself to a major pharmaceuticals company before the end of the year, according to analysts and other industry observers. (Full article: 686 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $9.95 1 month archives pass
- $24.95 3 months archives pass
- $74.95 1 year archives pass
